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Abstract
Objectives. To assess the prevalence of avascular necrosis (AVN) in a large cohort of patients with idiopathic inflammatory myopathies (IIM) and define the major associated risk factors.

Methods. We retrospectively reviewed the electronic medical records of all patients with a definitive diagnosis of
IIM enrolled in our registry between 2003 and 2017, and followed until 2020. Pertinent demographic, clinical, serologic
and imaging data were collected. A matched group of patients without AVN was then selected for comparison.
Results. A total of 1680 patients were diagnosed with IIM. Fifty-one patients developed AVN, with an overall prevalence
of 3%. Musculoskeletal MRI was available for 1085 patients and AVN was present in 46 patients (43 lower extremities
and 3 upper extremities MRI studies), with a relative prevalence of 4.2%. Most patients with AVN were Caucasian females
(57%) with a mean (S.D.) age at diagnosis of 44.5 (12.4) years. Sixty-one percent had DM and 29% had PM. The median
time from onset of IIM to diagnosis of AVN was 46 months. The hip joint was most commonly involved in 76% of cases,
followed by the knee joint in 15% and shoulder joint in 9%. Some 81% of patients were asymptomatic. Established risk
factors for AVN were not found to be associated with the development of AVN in IIM patients.
Conclusion. Although mostly asymptomatic and incidental, the overall prevalence of AVN in IIM was 3% and the
prevalence by MRI was 4.2%. None of the established risk factors was found to be associated with AVN development.
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Rheumatology key messages
Prevalence of avascular necrosis in a large single-centre cohort of idiopathic inflammatory myopathies was 3%.
Most cases were asymptomatic, revealed on musculoskeletal MRI done for evaluation of idiopathic inflammatory
myopathies.
. Established risk factors were not associated with avascular necrosis development in idiopathic inflammatory
myopathies.
.
.
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Introduction
Avascular necrosis (AVN), also known as osteonecrosis
when diaphyseal in location, is the death of bone due to
interruption of vascular supply. Although AVN is often
related to a direct trauma, it is not unusual to observe
this complication in a variety of systemic diseases, particularly when other well-recognized risk factors (e.g.
CS, alcohol or tobacco use, or hyperlipidaemia) are
associated [1]. AVN is a frequently reported complication of systemic inflammatory illnesses, such as SLE
and IBD [2–4], with strong attribution to CS exposure
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Methods
Patient population
This is a retrospective observational study that included
all patients enrolled in the Johns Hopkins Myositis
Registry between January 2003 and December 2017,
and followed until December 2020. Written informed
consents were obtained from all patients included in the
registry. This study was covered by the Johns Hopkins
Institutional Review Board approval number NA0007454.
In order to identify patients who developed AVN, the
electronic medical record (The Johns Hopkins EPIC
Electronic Medical Record) was queried for keywords
including ‘avascular necrosis’, ‘AVN’ and ‘osteonecrosis’
(Fig. 1). Patients’ electronic medical records were then
reviewed and pertinent demographic, clinical and imaging data collected including: age at myositis diagnosis,
sex, race, AVN diagnosis date, presence of symptoms
at AVN diagnosis, presence of major risk factors for
AVN [HIV infection, hyperlipidaemia, alcohol consumption (recorded as drinkers vs non-drinkers), tobacco use
(recorded as active/former smoker vs never smoked),
CS use (recorded as never/ever as well as highest dose
prescribed in the 6 months prior to diagnosis of AVN)].
Subsequently, the highest prednisone dose prescribed

was grouped into intervals (i.e. 1–10, 11–20, 21–30 and
>30 mg/day) to assess for dose-related effect. All
patients in our cohort underwent auto-antibody profile
phenotyping by Euroimmun EUROLINE (Lubeck,
Germany). Positive values were based on manufacturer’s guidelines of 15/þ. The diagnosis of AVN was
based on imaging findings (MRI, CT or X-ray). MRI or
radiograph reports with description and site of AVN
were reviewed. The duration of IIM was calculated from
the date of onset of first IIM symptom (i.e. weakness,
myalgia, RP, dyspnoea, dysphagia or rash attributable
to IIM) until the date of death, last follow-up or administrative censor date of 25 December 2020, whichever
came first. All patients included in this study had a diagnosis of IIM and they were classified in one of five mutually exclusive clinical subgroups. Thus, patients were
classified as having immune-mediated necrotizing myositis if they met the 2003 European Neuromuscular
Centre criteria, IBM if they fulfilled European
Neuromuscular Centre criteria or clinically amyopathic
DM if they met Sontheimer’s criteria [6–9]. If none of
these three criteria was met, patients were evaluated for
Bohan and Peter criteria and classified accordingly as
possible, probable or definite DM or PM [10, 11].
Patients with IBM were then excluded from analysis.

Image acquisition
Imaging was comprised of radiography, CT and MRI.
Radiography was comprised of anteroposterior and lateral projects of the hip. CT was performed according to
institutional protocol (120 kV), 147 mAS, acquisition time
5–7 s, collimation 128  0.6 mm, pitch 0.6 and craniocaudal scan direction. CT studies were prompted by
symptoms and the body regions scanned included the
shoulders and abdomen/pelvis. MRI of bilateral thighs
was performed using institutional myositis protocol

FIG. 1 Selection flowchart

IIM: idiopathic inflammatory myopathies; EMR: electronic medical records; AVN: avascular necrosis.
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[5]. Idiopathic inflammatory myopathies (IIM), a heterogeneous group of autoimmune disorders that predominantly affect skeletal muscles, share with SLE many
clinical, pathogenic and therapeutic features (musculoskeletal presentation, autoimmunity and CS use, respectively). However, unlike in SLE, few studies
describing AVN in IIM exist. Hence, we sought to assess
the prevalence of AVN in our IIM cohort and define
associated risk factors.

Prevalence of avascular necrosis in idiopathic inflammatory myositis: a single-centre experience

FIG. 2 Example image of AVN on MRI

comprised of fluid sensitive short tau inversion recovery,
or STIR [repetition time (TR), 3500–6800 ms, echo time
(TE), 42–58 ms, slice thickness (ST) 6–7 mm, inter-slice
gap 1 mm] and T1-weighted (TR 680–790 ms, TE 8–
12 ms, slice ST 5–6 mm, inter-slice gap 1 mm) sequence
in the axial and coronal plane with field of view spanning
from iliac crests to knees. (Fig. 2) While the majority of
MRI studies were performed to assess for myositis of
the proximal lower extremities, in three instances symptoms prompted MRI of the shoulders.

Image interpretation (diagnostic criteria for AVN/
osteonecrosis)
Musculoskeletal fellowship-trained radiologists interpreted all imaging. On radiography and CT, presence of
peripheral undulating or serpentine sclerosis with intermixed regions of central lucency with or without subarticular collapse (when involving the epiphysis), articular
surface fragmentation or secondary OA was interpreted
as AVN (when epiphyseal) or osteonecrosis (when

https://academic.oup.com/rheumatology

diaphyseal in location). Similarly, on MRI, presence of
fatty marrow with peripheral undulating or serpentine
sclerosis or hypointense signal on all sequences or a
‘double-line’ sign indicative of outer low-signal intensity
rim of sclerosis and inner high-signal intensity rim of
granulation tissue/reactive interface visible on fluid sensitive sequences was interpreted as AVN or osteonecrosis. When AVN or osteonecrosis was present, the
anatomic location was documented in the radiology report. Due to the lack of available radiography in all
patients and large field of view for MRIs optimized
for the evaluation of skeletal thigh muscles rather than
subarticular bone, staging of AVN was not performed
[12, 13].

Statistical analysis
Data are reported as number of cases (percentage) and
continuous variables are shown as mean 6 S.D. or median (range), as appropriate. A 3:1 matching group of
patients without history/diagnosis of AVN was randomly
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A 41-year-old woman with history of DM and AVN detected on thigh MRI. Coronal and axial T1-weighted (A and B)
and STIR (C and D) sequences performed through bilateral thighs as per myositis protocol show bilateral right (long
arrow) greater than left (short arrow) femoral head AVN characterized by serpentine elevated STIR and dark T1 signal
abnormality in the bilateral femoral heads with preservation of fat signal in the subarticular bone. AVN: avascular necrosis; STIR: short tau inversion recovery.
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Results
Prevalence of AVN
Among 1680 patients who were evaluated and diagnosed with IIM between 2003 and 2020, 51 had developed AVN on documented imaging with a median (min,
max) time from IIM diagnosis of 46 months (338, 384).
The overall prevalence of AVN was 3% (51/1680).
Musculoskeletal MRI (MSK MRI) was available for 1085
patients, and 46 of 51 patients with AVN were diagnosed with MSK MRI, therefore the relative prevalence
(on MRI) was calculated to be 4.2% (46/1085).

TABLE 1 Demographic and clinical characteristics of
patients with AVN and myositis
Myositis with
AVN, n (%)
Number of patients
51
Gender
Men
15 (29)
Women
36 (71)
Race
White
29 (57)
Black
15 (29)
Asian
1 (2)
Hispanic
2 (4)
Other
4 (8)
Age at myositis onset, years
43.9 (12.1)
Duration of IIM, years
10.2 (4.5)
Diagnosis
31 (61)
DM
15 (29)
PM
2 (4)
AD
3 (6)
IMNM
Site of AVN
42 (76)
Hip joint
8 (15)
Knee joint
5 (9)
Shoulder joint
Symptomatic AVN
10 (19)
Recurrent AVN
5 (10)
Surgical correction
10 (19)
Age at AVN diagnosis, years
44.5 (12.4)
Time from myositis to AVN, months (range) 46 (338, 384)

Patients with IIM and AVN
The demographic and clinical characteristics of these
patients are reported in Table 1. In the AVN group, the
majority of patients were White, middle-aged women
[71% women, 57% White, and mean age at myositis
diagnosis 44.5 (12.4) years]. Sixty-one percent of these
patients were diagnosed with DM, and 29% with PM.
Nine of 51 patients (17%) were diagnosed with AVN before being diagnosed with IIM, and 6 of them were
exposed to CS (prednisone equivalent dose in mg: 40,
100, 80, 10, 10, 10). Only 10 patients (19%) had symptoms upon their AVN diagnosis (reported symptoms
included joint pain and ambulation difficulty). The hip
joint was most frequently involved, in 76% of cases
(femoral head/neck 60%, acetabula 16%), followed by
the knee joint in 15% and shoulder joint in 9%. AVN
diagnosis was confirmed by MRI in 46 patients (90%).
Of the 46 cases of AVN on MRI, 43 cases were diagnosed by lower extremities MRI studies that anatomically include the hip through the distal femur and 3 cases
by upper extremities MRI that included mainly the
shoulders. AVN was diagnosed by CT scan in three
patients (6%), CT scan of the shoulders in two patients
and abdomen/pelvis in one patient. Two patients (4%)
had their AVN diagnosed by hip X-ray. Ten patients
required surgical repair for their AVN (seven patients
had core decompression and three patients had total replacement of the joint), and only three (30%) were
symptomatic.

4

Data are expressed in number of cases (%), mean (S.D.) or
median (min, max). AD: amyopathic dermatomyositis; AVN:
avascular necrosis; IIM: idiopathic inflammatory myopathies; IMNM: immune-mediated necrotizing myositis.

IIM with AVN vs IIM without AVN
One hundred and fifty-three patients were selected as
matches for the in-study group of IIM-AVN. Baseline
demographics were similar between the two groups
including sex, race and age at myositis onset. In the IIM
AVN group, there were fewer patients with DM (61 vs
72%, P < 0.01) as compared with the matched group.
None of the major recognized risk factors for AVN (history of cancer, tobacco use, alcohol use or CS use) was
found to be significantly associated with AVN. Similarly,
no myositis-specific or myositis-associated autoantibodies were significantly associated with AVN (Table 2).

Predictors of AVN development
Univariable regression analyses were performed for all
the major risk factors for AVN previously described.
None of the examined factors was shown to have significant associations (Table 3). Of note, neither prednisone use as single variable (ever/never) nor any of the
dose interval categories assessed separately were found
to be associated with AVN development.
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selected and matched on the following criteria: age at
IIM diagnosis 65 years, duration of IIM 62 years. As in
the AVN group, IBM patients were excluded from the
matching pool. Group comparisons were made using
Student’s t-test for continuous variables and v2 statistics
for categorical variables. A P-value <0.05 was considered significant. To examine the relationship between
multiple major known risk factors for AVN and the development of AVN in a large myositis cohort, univariable logistic regression was performed. Statistical analyses
were performed using SPSS Statistics 27.0.1.0 (IBM
Corp., Armonk, NY, USA).

Prevalence of avascular necrosis in idiopathic inflammatory myositis: a single-centre experience

TABLE 2 Risk factors and serology in myositis with AVN vs myositis without AVN
Myositis without AVN

31 (61)
15 (29)
2 (4)
3 (6)

110 (72)
43 (28)
0
0

4 (8)
13 (24)
10 (20)
2 (4)
18 (35)
45 (89)
20 (5, 100)

15 (10)
48 (31)
–
–
41 (27)
138 (90)
10 (2, 40)

5 (10)
5 (10)
5 (10)
0 (0)
1 (2)
10 (20)
5 (10)
4 (8)
2 (4)
4 (8)
5 (10)
2 (4)
6 (12)
3 (6)
00

10 (7)
25 (16)
6 (4)
2 (1)
0 (0)
20 (13)
15 (10)
10 (7)
5 (3)
13 (9)
17 (11)
9 (6)
8 (5)
9 (6)
2 (1)

IIM type
DM
PM
AD
IMNM
AVN risk factors
History of cancer, yes
History of tobacco use, yes
History of hyperlipidemia, yes
History of HIV, yes
History of alcohol use, yes
History of steroid use, yes
Prednisone equivalent dose used, mg/day
Serology
Anti-PL12, positive
Anti-Jo1, positive
Anti-PL7, positive
Anti-EJ, positive
Anti-OJ, positive
Anti-T1F1g, positive
Anti-MDA5, positive
Anti-NXP2, positive
Anti-Ku, positive
Anti-SRP, positive
Anti-PM75, positive
Anti-PM100, positive
Anti-Mi2b, positive
Anti-Mi2a, positive
Anti-SAE1, positive

P-value
0.001

NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS

Data are expressed in number of cases (%) or median (min, max). AD: amyopathic dermatomyositis; AVN: avascular necrosis; IIM: idiopathic inflammatory myopathies; IMNM: immune-mediated necrotizing myositis; NS: not significant.

TABLE 3 Univariate logistic regression analysis, predictors of developing AVN in myositis population
Variable

OR

95% CI (min, max)

Sex, female
Race, white
History of cancer, yes
History of alcohol use, yes
History of tobacco use, yes
History of steroid use, yes
Daily PED range, mg (1–10)
11–20
21–30
>30 mg

0.90
0.69
0.78
1.49
0.67
0.81
2.33
1.55
1.56
1.11

0.45, 1.82
0.36, 1.33
0.24, 2.47
0.75, 2.93
0.32, 1.39
0.29, 2.22
1.68, 4.28
1.81, 3.12
0.33, 7.31
0.08, 15.03

P-value
0.78
0.27
0.67
0.24
0.28
0.69
0.92
0.56
0.71
0.93

AVN: avascular necrosis; OR: odds ratio: PED: prednisone equivalent dose.

Discussion
Our study demonstrated an overall AVN prevalence of
3% and a relative prevalence of 4.7% considering only
cases with available MRI among patients with diagnosis
of IIM. The major recognized risk factors for atraumatic
AVN were assessed in this population and none was
found to be significantly associated.

https://academic.oup.com/rheumatology

Although AVN is known to be a disabling complication
of multiple rheumatic/systemic diseases, it has been
studied most in SLE. High AVN incidence and prevalence rates in SLE populations have been attributed to
common risk factors in this population (e.g. CS use, inflammation and thrombophlebitis) [14–16]. The prevalence of AVN in SLE has ranged in different studies
between 4 and 15% [17–19]. In a Canadian study of
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of our MSK MRI protocol of the bilateral proximal lower
extremities performed on all patients at the time of IIM
evaluation allows for a comprehensive capture of both
symptomatic and asymptomatic cases in that anatomic
distribution. While many incidental and asymptomatic
cases of AVN were discovered, the diagnosis of AVN at
early stages is crucial to allow time for interventions to
preserve the joint and prevent collapse. Such interventions include pharmacologic agents (e.g. lipid-lowering
agents, anticoagulation and bisphosphonates), biophysical treatment and joint-preserving surgeries (e.g. core
decompression) [27]. Of the 10 patients who had surgical repair in our study, 7 (70%) had only core decompression in the pre-collapse phase and did not require
joint replacement.
While the size of our study and standardized MRI assessment are strengths of our study, we acknowledge
several limitations exist. First, we might have missed
patients who had AVN in our cohort of IIM, either if their
clinical notes did not include the queried keywords
(avascular necrosis, AVN and osteonecrosis), if the
imaging study was done in an outside hospital or if they
developed asymptomatic AVN after the initial MRI assessment. Of note, we attempted to contact the primary
physician of all patients who had uncertain history of
AVN in their records. Second, the majority of incidental
AVN were revealed on lower-extremity MRI studies performed for IIM diagnosis, which can potentially underestimate asymptomatic upper-extremity AVN cases.
Additionally, limited information was available regarding
the quantity of alcohol and tobacco used in the study
patients, prompting dichotomous reporting of users vs
non-users, which might have affected the accuracy of
the risk relationship between these two factors and AVN
development. Finally, we only considered the highest
dose of CS used in our patients, since we were unable
to obtain an accurate measure of a cumulative dose.
However, in the absence of a standardized method to
assess the dose of CS used, we believe that considering
the highest dose used in the last 6 months prior to AVN
diagnoses is reasonable [28].

Conclusions
In this retrospective study, the prevalence of AVN in a
large cohort of patient with IIM was found to be 3%,
and slightly higher (4.2%) if we considered AVN diagnosed only on MRI. AVN was diagnosed by MSK MRI of
the proximal lower extremities that was mainly part of
the IIM diagnostic protocol in 90% of the cases, and the
majority (81%) were asymptomatic. None of the major
recognized risk factors for AVN was found to be significantly associated with AVN. Similarly, no myositisspecific or myositis-associated autoantibodies were significantly associated with AVN.
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1729 SLE patients followed prospectively since 1970,
13.5% developed symptomatic AVN, with strong association with steroid use [20]. Unlike in SLE, the literature on
AVN in IIM has been limited to case series/reports [21].
Huang et al. reported an AVN incidence of 11.6% (15/
129) in patients with PM/DM (PM 3/27, DM 12/87) who
underwent whole-body MRI to diagnose muscular and
extra-muscular lesions [22]. All patients were exposed to
CS and most of them were asymptomatic (87%). In comparison, our study was similar in that the majority of
patients were asymptomatic and the hip joint was most
commonly affected. In contrast, we report a lower prevalence of AVN in IIM, perhaps due to only having MRI
data on limited extremities rather than whole body.
Although the routine use of MRI to assess potential IIM is
more likely to reveal subclinical/asymptomatic AVN in our
practice, the prevalence of AVN in SLE is substantially
higher. This could be, in part, attributed to the higher
doses of CS usually prescribed and possibly to the procoagulant state that exists in SLE. In SLE, CS use was
associated with increased AVN at a maximum daily prednisone dose of at least twice the dose used in our
patients [23].
While CS were not significantly associated with AVN
in our study, those who developed AVN had twice the
median dose of steroid (20 vs 10 mg/day) prior to AVN
diagnosis. Despite the difference in median dose of steroid between AVN group and controls, the dose interval
categories did not reveal a specific dose-dependent relationship with AVN. The pathogenesis of steroidinduced osteonecrosis is unclear; however, several theories have been proposed. Steroid use may lead to fat
mobilization and increased blood lipid levels with higher
risk of fat microvascular embolization, medullary fat accumulation and increased volume of adipocytes, which
can cause insufficient blood supply. Additionally, steroids can possibly decrease osteogenesis of bone marrow mesenchymal stem cells, cause local bone
inflammation and increase apoptosis [24].
Alcohol consumption was not associated with AVN
development in our IIM patients. The pathogenesis of
alcohol-induced AVN is not well known, but several
mechanisms including increased adipogenesis and
diminished haematopoiesis in the bone have been suggested [25]. In a meta-analysis, Yoon et al. analysed five
studies that reported an association between alcohol intake (both current consumption and cumulative amount)
and AVN development [26]. In our study, we assessed
the history of alcohol consumption during or before AVN
diagnosis in a dichotomous manner (regular drinkers vs
non-drinkers), without being able to quantify the amount
consumed given the nature of the study. None of the
myositis-specific or myositis-associated autoantibodies
was significantly associated with AVN. This observation
might be due to small sample size and a very low frequency of certain antibodies (e.g. anti-OJ positivity in
only one case of IIM with AVN).
To our knowledge, this is the largest study examining
the prevalence of AVN in IIM. The standardized nature
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